Navigation Links
Hungarian Cancer Formula Producer Questions U.S. Introduction of AveUltra
Date:11/17/2009

BUDAPEST, Hungary, Nov. 17 /PRNewswire/ -- Hungarian drug producer Biropharma and patent holders of its main product Avemar dispute the connection American BioSciences Inc. and its partner Mate Hidvegi are making between their recently introduced product AveUltra and Avemar, a dietary supplement being used in cancer treatment internationally for 11 years.

"AveUltra and Avemar are two different sets of compounds hence the qualities of Avemar can be attributed exclusively to Avemar, therefore all references of AveUltra to Avemar is scientifically unfounded, deceptive and abundantly unethical," Avemar's co-inventors state on Avemar's website (www.avemar.com).

Avemar is a wheat germ extract formula under patent protection designed to treat cancer patients. It is produced by Biropharma based on a definite-term contract with the holders of its patent. The product is distributed under the brand 'Ave' in the U.S.

Hidvegi, one of the patent holders, has teamed up with American BioSciences to start the U.S.-based production of AveUltra, a dietary supplement also based on wheat germ extract, but different from Avemar. According to their claims, AveUltra is developed from Avemar, however, no scientific or otherwise experimental data supports this assertion.

Several clinical studies investigated the various benefits associated with Avemar treatment and the results were published in prestigious peer reviewed medical journals. These publications cannot be used to support the claims of AveUltra.

The producers of AveUltra planned to announce the start of U.S.-based manufacturing of AveUltra at the Society of Integrative Oncology's 6th International Conference at the New York Academy of Medicine on Nov. 12-13.

Avemar's Hungarian producer Biropharma, three co-inventors and a patent holder of Avemar are disputing the steps and behavior of American
'/>"/>

SOURCE Biropharma
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Oncolytics Biotech(R) Inc. Collaborators Present Positive Phase I/II Trial Results in Advanced Solid Cancers with a Focus on the Head and Neck at the AACR-NCI-EORTC Meeting
2. Biomodels Scientists Report Development of a Novel Model for Cancer Treatment-Related Fatigue
3. Hollis-Eden Presents New Interim Data From Prostate Cancer Phase I/II Clinical Studies of Apoptone (HE3235) at AACR Molecular Targets and Cancer Therapeutics Conference
4. Axelar AB Presents the New Anticancer Agent AXL1717 at The AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston, Massachusetts, USA
5. Hollis-Eden to Present Interim Data From Its Phase I/II Clinical Studies of Apoptone(R) (HE3235) at Molecular Targets and Cancer Therapeutics Conference
6. Champions Biotechnology to Present Data at AACR-EORTC 2009 Regarding the Predictability of Biomerk Tumorgraft(TM) Platform to Guide Personalized Cancer Treatment and Accelerate Oncology Drug Development
7. Reportlinker Adds Cancer Vaccines: Measuring Market Potential
8. Texas State University Prepares for Phase 2 Research on the Potential New Cancer and HIV Fighting ALKA-V6 Compound
9. Precision Antibody Wins Contract to Develop Gold Standard Antibodies as Part of National Cancer Institutes Clinical Proteomics Technologies for Cancer (CPTC) Initiative
10. Ipsen and Debiopharm Group Announce That Decapeptyl(R)(triptorelin embonate) 6-month Successfully Completes the European Decentralised Procedure for the Treatment of Locally Advanced or Metastatic Prostate Cancer
11. Clinical Remissions in Three Otherwise Intractable Cancers Signal the Progress of Targeted Genetic Medicine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... 23, 2014  Sofinnova Ventures, a Menlo ... closing of Sofinnova Venture Partners IX, L.P. at the ... the initial fund target of $425 million. ... companies. Consistent with recent funds, SVP IX will provide ... programs, along with select investments in earlier stage opportunities. ...
(Date:7/23/2014)... July 23, 2014 Adult stem ... therapies are biological, but not magical. However, ... to treat them as if they were magical. ... unsanctioned studies that constitute “stem cell tourism,” are ... approach to developing new regenerative medicine therapies. In ...
(Date:7/22/2014)... the National Institute of Standards and Technology (NIST) ... a new design for an atomic clock that ... a microcomb. , The microcomb clock, featured on ... new journal Optica ,* is the first ... its accurate conversion of optical frequencies to lower ...
(Date:7/22/2014)... Fla. (PRWEB) July 22, 2014 CTD ... for the pharmaceutical, medical device, cosmetics, and other markets, ... Placement with a group of qualified private investors led ... , The transaction involved the signing ... issued 1,725,000 shares of Common Stock at a price ...
Breaking Biology Technology:Sofinnova Raises $500 Million Biotech Venture Fund 2The Adult Stem Cell Technology Center, LLC Continues to Develop Technologies for Homologous Adult Stem Cell Therapies and Drug Development 2The Adult Stem Cell Technology Center, LLC Continues to Develop Technologies for Homologous Adult Stem Cell Therapies and Drug Development 3The Adult Stem Cell Technology Center, LLC Continues to Develop Technologies for Homologous Adult Stem Cell Therapies and Drug Development 4The Adult Stem Cell Technology Center, LLC Continues to Develop Technologies for Homologous Adult Stem Cell Therapies and Drug Development 5'Comb on a chip' powers new NIST/Caltech atomic clock design 2CTD Holdings Closes $1.725 Million Private Placement 2CTD Holdings Closes $1.725 Million Private Placement 3
... March 4 SGX Pharmaceuticals,(Nasdaq: SGXP ) ... and,full year 2007 on Wednesday, March 12, 2008. ... call and webcast at 8:00 a.m. Pacific Time.,Mike ... Myers, Chief,Financial Officer, will host the conference call ...
... PHILADELPHIA - For centuries, engineers have bent and torn ... scientists at the University of Pennsylvania School of Engineering ... at nanoscale sizes in the form of wires a ... has enable Penn engineers to construct a theoretical model ...
... Achieves 2007 Net Income of $13.1 Million, DUBLIN, ... a pharmaceutical company dedicated to the discovery, rapid,development and ... reported financial results for the fourth,quarter and year ended ... for the 2007 fourth quarter of $5.1,million, or $0.09 ...
Cached Biology Technology:SGX Pharmaceuticals Schedules Teleconference and Webcast for Fourth Quarter and Full Year 2007 Results 2Surface dislocation nucleation: Strength is but skin deep at the nanoscale, Penn engineers discover 2SuperGen Reports 2007 Fourth Quarter and Annual Financial Results 2SuperGen Reports 2007 Fourth Quarter and Annual Financial Results 3SuperGen Reports 2007 Fourth Quarter and Annual Financial Results 4SuperGen Reports 2007 Fourth Quarter and Annual Financial Results 5SuperGen Reports 2007 Fourth Quarter and Annual Financial Results 6SuperGen Reports 2007 Fourth Quarter and Annual Financial Results 7SuperGen Reports 2007 Fourth Quarter and Annual Financial Results 8SuperGen Reports 2007 Fourth Quarter and Annual Financial Results 9SuperGen Reports 2007 Fourth Quarter and Annual Financial Results 10SuperGen Reports 2007 Fourth Quarter and Annual Financial Results 11SuperGen Reports 2007 Fourth Quarter and Annual Financial Results 12
(Date:7/23/2014)... alongside decades of in-depth monitoring, has provided unique ... a population of top-predators. Published in Nature ... seals have significantly altered in accordance with changes ... conditions. Despite a shift in the population towards ... through generations, leaving the population in decline. ...
(Date:7/23/2014)... a high health risk warning for Yellowknife and surrounding ... to forest fires. In the image taken by ... normal wind patterns. Fire is an obvious health ... not quite so obvious and its effects are insidious. ... (forest, brush, crop, structure, tires, waste or wood burning) ...
(Date:7/23/2014)... 780 million people around the world have no access ... Organization (WHO), 3.4 million people die from water-related diseases ... goal of making a contribution to solving this problem. ... Stark, head of the Functional Materials Laboratory, the 23-year-old ... a prototype. , "What makes our DrinkPure filter unique ...
Breaking Biology News(10 mins):Genetic study shows major impact of climate change on Antarctic fur seals 2Genetic study shows major impact of climate change on Antarctic fur seals 3ETH student develops filter for clean water around the world 2
... University of California, San Diego NanoEngineers won a ... develop the tools to manufacture biodegradable frames around which ... grow. Developing methods for growing tissues that mimic nature,s ... efforts to grow replacement cardiac tissues for people who ...
... University of Illinois researchers are using a new kind of ... the relationship between cell mass and growth rate. ... professor Rashid Bashir, published its results in the online early ... Sciences . "It,s merging micro-scale engineering and cell biology," ...
... Nov. 15, 2010 Tiny molecules called microRNAs ... labor, raising the prospect that RNA-based drugs might be ... Medical Center have discovered in a preclinical study. ... controls labor, so with future research we might have ...
Cached Biology News:Nanoengineers aim to grow tissues with functional blood vessels 2Nanoengineers aim to grow tissues with functional blood vessels 3Microsensors offer first look at whether cell mass affects growth rate 2Tiny RNA molecules control labor, may be key to blocking premature birth 2
Request Info...
"BioTracker 6X Bromophenol Blue Tracking Dye is composed of 60% St DI H2O, 30% Glycerol, 10% 10XTE, 0.25% BPB Dye and 0.85% SDS....
Request Info...
Request Info...
Biology Products: